HC Wainwright Has Bearish Forecast for Septerna Q4 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Research analysts at HC Wainwright decreased their Q4 2025 earnings estimates for Septerna in a note issued to investors on Tuesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their prior estimate of $0.87. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.25 EPS.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of Septerna in a research report on Friday, September 5th. Wall Street Zen downgraded Septerna from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.75.

Septerna Stock Up 0.1%

NASDAQ:SEPN opened at $19.24 on Thursday. The stock has a market capitalization of $861.37 million and a price-to-earnings ratio of -12.74. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The firm has a 50 day moving average of $19.17 and a 200 day moving average of $13.65.

Institutional Trading of Septerna

Several large investors have recently added to or reduced their stakes in SEPN. KLP Kapitalforvaltning AS purchased a new position in shares of Septerna in the first quarter worth about $49,000. XTX Topco Ltd acquired a new position in Septerna in the 1st quarter worth approximately $216,000. Chicago Partners Investment Group LLC purchased a new position in Septerna during the 1st quarter worth approximately $63,000. TRV GP VI LLC lifted its stake in Septerna by 33.6% during the 1st quarter. TRV GP VI LLC now owns 4,211,659 shares of the company’s stock valued at $24,386,000 after acquiring an additional 1,059,203 shares during the period. Finally, Deutsche Bank AG boosted its holdings in shares of Septerna by 53.3% in the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock valued at $92,000 after acquiring an additional 5,549 shares during the last quarter.

Insider Buying and Selling at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the transaction, the senior vice president directly owned 92,911 shares of the company’s stock, valued at $1,677,972.66. This represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by company insiders.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.